Published in Proc Natl Acad Sci U S A on November 06, 2006
Molecular basis of calcium signaling in lymphocytes: STIM and ORAI. Annu Rev Immunol (2010) 5.11
Th17 cells in human disease. Immunol Rev (2008) 4.27
The functional network of ion channels in T lymphocytes. Immunol Rev (2009) 3.21
Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov (2009) 3.12
Prediction and pathogenesis in type 1 diabetes. Immunity (2010) 2.26
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc Natl Acad Sci U S A (2008) 2.22
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol (2012) 1.74
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proc Natl Acad Sci U S A (2013) 1.64
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev (2008) 1.52
Ion channels: functional expression and therapeutic potential in cancer. Colloquium on Ion Channels and Cancer. EMBO Rep (2008) 1.46
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A (2010) 1.29
Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol (2009) 1.29
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther (2012) 1.19
Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets (2011) 1.15
Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol (2008) 1.14
Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One (2008) 1.12
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol (2009) 1.08
Hg1, novel peptide inhibitor specific for Kv1.3 channels from first scorpion Kunitz-type potassium channel toxin family. J Biol Chem (2012) 1.07
Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) (2007) 1.06
From foe to friend: using animal toxins to investigate ion channel function. J Mol Biol (2014) 1.04
Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol (2010) 1.03
The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell (2009) 1.03
Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc (2009) 1.02
A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma. PLoS One (2013) 0.99
Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain (2010) 0.98
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res (2011) 0.98
Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol (2012) 0.98
A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One (2013) 0.96
Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol (2012) 0.96
Optogenetic photochemical control of designer K+ channels in mammalian neurons. J Neurophysiol (2011) 0.95
Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem (2014) 0.94
The immunological synapse: a dynamic platform for local signaling. J Clin Immunol (2010) 0.94
Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. Toxicon (2012) 0.94
Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model. J Biol Chem (2012) 0.93
IgE-dependent signaling as a therapeutic target for allergies. Trends Pharmacol Sci (2012) 0.92
KCa1.1 potassium channels regulate key proinflammatory and invasive properties of fibroblast-like synoviocytes in rheumatoid arthritis. J Biol Chem (2011) 0.91
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A (2009) 0.91
Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands. Brain Res (2012) 0.91
Autoimmune effector memory T cells: the bad and the good. Immunol Res (2013) 0.91
A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett (2012) 0.90
A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep (2014) 0.90
Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol (2010) 0.89
Kv1.3 channels in postganglionic sympathetic neurons: expression, function, and modulation. Am J Physiol Regul Integr Comp Physiol (2008) 0.89
Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One (2013) 0.89
Antibody-guided photoablation of voltage-gated potassium currents. J Gen Physiol (2013) 0.89
Drawing blood from rats through the saphenous vein and by cardiac puncture. J Vis Exp (2007) 0.87
Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells. PLoS One (2013) 0.86
T cells in vascular inflammatory diseases. Front Immunol (2014) 0.85
Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors. Biochim Biophys Acta (2011) 0.85
Kv1.3 channels modulate human vascular smooth muscle cells proliferation independently of mTOR signaling pathway. Pflugers Arch (2014) 0.85
Physiological role of Kv1.3 channel in T lymphocyte cell investigated quantitatively by kinetic modeling. PLoS One (2014) 0.84
Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J (2014) 0.84
Computational studies of marine toxins targeting ion channels. Mar Drugs (2013) 0.84
HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity. PLoS One (2013) 0.84
Blockade of Kv1.3 channels ameliorates radiation-induced brain injury. Neuro Oncol (2013) 0.84
Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity. Cell Death Dis (2012) 0.83
HIV-1 gp120 enhances outward potassium current via CXCR4 and cAMP-dependent protein kinase A signaling in cultured rat microglia. Glia (2011) 0.83
Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. PLoS One (2012) 0.82
KCa1.1 inhibition attenuates fibroblast-like synoviocyte invasiveness and ameliorates disease in rat models of rheumatoid arthritis. Arthritis Rheumatol (2015) 0.82
The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker. PLoS One (2012) 0.82
Structural and functional diversity of acidic scorpion potassium channel toxins. PLoS One (2012) 0.82
Transcriptome analysis of scorpion species belonging to the Vaejovis genus. PLoS One (2015) 0.82
Modulation of T lymphocyte calcium influx patterns via the inhibition of kv1.3 and ikca1 potassium channels in autoimmune disorders. Front Immunol (2013) 0.82
Ion channels and anti-cancer immunity. Philos Trans R Soc Lond B Biol Sci (2014) 0.82
Kv1.3: a potential pharmacological target for diabetes. Acta Pharmacol Sin (2010) 0.82
The role of PSD-95 in the rearrangement of Kv1.3 channels to the immunological synapse. Pflugers Arch (2013) 0.82
Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions. Nat Commun (2017) 0.82
Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis (2014) 0.81
Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers. PLoS One (2012) 0.81
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem (2008) 0.81
Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity. Biomaterials (2013) 0.81
Immunology and neurology. J Neurol (2007) 0.80
Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem (2010) 0.80
Plectasin, first animal toxin-like fungal defensin blocking potassium channels through recognizing channel pore region. Toxins (Basel) (2015) 0.79
Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. J Autoimmun (2014) 0.79
Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life. J Biol Chem (2014) 0.79
Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics. Future Med Chem (2014) 0.79
Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease. J Alzheimers Dis (2015) 0.79
Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel. Sci Rep (2015) 0.79
The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLoS One (2013) 0.79
Molecular Determinants of Kv1.3 Potassium Channels-induced Proliferation. J Biol Chem (2015) 0.79
Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases. Toxins (Basel) (2015) 0.78
Ion channel engineering: perspectives and strategies. J Mol Biol (2014) 0.78
Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun (2016) 0.78
A C-terminal PDZ binding domain modulates the function and localization of Kv1.3 channels. Exp Cell Res (2011) 0.78
N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J (2015) 0.78
Targeting ion channels for the treatment of autoimmune neuroinflammation. Ther Adv Neurol Disord (2013) 0.78
Kv1.3 contains an alternative C-terminal ER exit motif and is recruited into COPII vesicles by Sec24a. BMC Biochem (2015) 0.78
Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation. Sci Rep (2016) 0.77
Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL. J Lipid Res (2012) 0.77
New Trends in Cancer Therapy: Targeting Ion Channels and Transporters. Pharmaceuticals (Basel) (2010) 0.77
Mapping the Interaction Anatomy of BmP02 on Kv1.3 Channel. Sci Rep (2016) 0.77
Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Mar Drugs (2015) 0.77
Inhibition of Kv channel expression by NSAIDs depolarizes membrane potential and inhibits cell migration by disrupting calpain signaling. Biochem Pharmacol (2015) 0.77
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature (1984) 4.70
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A (2001) 2.63
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther (2006) 2.48
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest (2002) 1.95
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
Subset-specific expression of potassium channels in developing murine T lymphocytes. Science (1988) 1.80
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest (2001) 1.74
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist (2005) 1.32
Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci U S A (2004) 1.31
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis (2006) 1.24
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol (2003) 1.16
Pristane, a non-antigenic adjuvant, induces MHC class II-restricted, arthritogenic T cells in the rat. J Immunol (2006) 1.15
Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells. Diabetes (2004) 1.11
Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain (2006) 1.09
Signalling during hypoxia in human T lymphocytes--critical role of the src protein tyrosine kinase p56Lck in the O2 sensitivity of Kv1.3 channels. J Physiol (2006) 1.08
Genetics of the BB rat: association of autoimmune disorders (diabetes, insulitis, and thyroiditis) with lymphopenia and major histocompatibility complex class II. Endocrinology (1995) 1.06
Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis (2004) 1.05
Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J Autoimmun (1990) 1.01
Lack of voltage sensitive potassium channels and generation of membrane potential by sodium potassium ATPase in murine T lymphocytes. J Immunol (1993) 1.01
Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism. Am J Physiol Cell Physiol (2006) 0.99
Precursor frequencies of T-cells reactive to insulin in recent onset type 1 diabetes mellitus. J Autoimmun (2004) 0.98
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther (2005) 0.96
Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin Immunol (2005) 0.94
A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria. J Trop Pediatr (2004) 0.89
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. Infect Immun (2001) 0.87
Inhibition of altered peptide ligand-mediated antagonism of human GAD65-responsive CD4+ T cells by non-antagonizable T cells. Eur J Immunol (2004) 0.85
Effects of ginkgolide B, a platelet-activating factor inhibitor on insulitis in the spontaneously diabetic BB rat. Autoimmunity (1991) 0.84
A major histocompatibility complex class II restriction for BioBreeding/Worcester diabetes-inducing T cells. J Exp Med (1995) 0.82
Drug monitoring of quinine in men with nonsevere falciparum malaria: study in the Amazon region of Brazil. Ther Drug Monit (2001) 0.82
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. Neuroimage (2007) 5.23
Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr (2002) 5.13
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res (2008) 3.76
Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab (2004) 3.54
International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev (2005) 3.50
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord (2014) 3.36
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33
The functional network of ion channels in T lymphocytes. Immunol Rev (2009) 3.21
Genetics of type 1A diabetes. N Engl J Med (2009) 3.18
K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci (2004) 3.12
A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. Neuroimage (2009) 3.07
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol (2010) 2.99
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol Rev (2005) 2.73
Induction and monitoring of adoptive delayed-type hypersensitivity in rats. J Vis Exp (2007) 2.61
Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab (2009) 2.58
De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci U S A (2005) 2.57
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology (2012) 2.54
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev (2005) 2.39
Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology (2011) 2.37
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36
Prediction and pathogenesis in type 1 diabetes. Immunity (2010) 2.26
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity (2008) 2.23
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res (2005) 2.18
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr (2008) 2.05
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev (2003) 2.05
High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain (2007) 2.03
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler (2011) 2.02
Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes (2002) 2.01
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology (2010) 1.96
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord (2008) 1.95
Induction and monitoring of active delayed type hypersensitivity (DTH) in rats. J Vis Exp (2007) 1.94
Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology (2009) 1.92
Adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care (2003) 1.91
Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab (2011) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol (2008) 1.88
Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation (2009) 1.86
Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem (2007) 1.85
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am J Clin Nutr (2008) 1.83
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int (2008) 1.80
Diffusion tensor magnetic resonance imaging of Wallerian degeneration in rat spinal cord after dorsal root axotomy. J Neurosci (2009) 1.79
Functionally diverse complement of large conductance calcium- and voltage-activated potassium channel (BK) alpha-subunits generated from a single site of splicing. J Biol Chem (2005) 1.78
Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab (2003) 1.74
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
Development of an MR-compatible SPECT system (MRSPECT) for simultaneous data acquisition. Phys Med Biol (2010) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Retinal layer segmentation of macular OCT images using boundary classification. Biomed Opt Express (2013) 1.67
Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med (2006) 1.67
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol (2004) 1.65
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proc Natl Acad Sci U S A (2013) 1.64
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63